Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decline in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 189,100 shares, a decrease of 57.8% from the October 31st total of 448,000 shares. Based on an average daily trading volume, of 579,700 shares, the short-interest ratio is currently 0.3 days. Approximately 10.5% of the company’s stock are sold short.

Lixte Biotechnology Stock Performance

NASDAQ LIXT traded up $0.06 during trading hours on Friday, hitting $2.23. The company had a trading volume of 21,991 shares, compared to its average volume of 335,458. The company has a market cap of $5.02 million, a PE ratio of -1.29 and a beta of -0.17. The business has a 50 day moving average of $1.82 and a 200-day moving average of $2.09. Lixte Biotechnology has a 1-year low of $1.31 and a 1-year high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.